Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Phuong Vo

Internal Medicine Marrero, LA Medical Doctor

NPI 1265548416 CMS profile 330036

7521 Westbank Expy, Suite E, Marrero, LA 70072

Open in the dashboard

General payments

$7,531

457 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Phuong Vo of Marrero, LA is reported in the CMS Open Payments database as having received $7,531 across 457 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $688 35
2024 General $795 42
2023 General $1,108 69
2022 General $1,054 65
2021 General $1,561 103
2020 General $1,419 95
2019 General $907 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Phuong Vo
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Phuong Vo were reported at $688. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Phuong Vo Internal Medicine median Middle half National median
2019 $907 $159 $48–$570 $163
2020 $1,419 $119 $33–$402 $114
2021 $1,561 $135 $37–$521 $132
2022 $1,054 $141 $42–$496 $149
2023 $1,108 $149 $45–$519 $160
2024 $795 $154 $47–$537 $164
2025 $688 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,326 70 payments
  2. GlaxoSmithKline, LLC. $1,268 77 payments
  3. Novo Nordisk Inc $764 52 payments
  4. AbbVie, Inc. $716 48 payments
  5. Lilly USA, LLC $559 34 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $427 26 payments
  7. Novartis Pharmaceuticals Corporation $368 22 payments
  8. Astellas Pharma US Inc $316 9 payments
  9. Allergan Inc. $229 22 payments
  10. Biohaven Pharmaceuticals, Inc. $172 11 payments
  11. Other $1,386 86 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,221 451 payments
  2. Education $251 5 payments
  3. Gift $59 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,208 74 payments
  2. FARXIGA $747 37 payments
  3. Ozempic $669 47 payments
  4. RYBELSUS $656 46 payments
  5. BREZTRI $556 22 payments
  6. TRULICITY $440 26 payments
  7. JARDIANCE $437 26 payments
  8. UBRELVY $322 20 payments
  9. NURTEC ODT $300 21 payments
  10. AIRSUPRA $286 8 payments
  11. Other $3,939 251 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 143 drugs

Part D claims

9,516

Median for Internal Medicine: 777

Drug cost

$979,727

Median for Internal Medicine: $73,373

Branded share of claims

20.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 167 $212,686
Ozempic Semaglutide Brand 115 $144,975
Jardiance Empagliflozin Brand 69 $90,520
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 60 $71,406
Eliquis Apixaban Brand 58 $59,653
Trulicity Dulaglutide Brand 31 $53,685
Xarelto Rivaroxaban Brand 32 $41,904
Myrbetriq Mirabegron Brand 54 $35,051
Linzess Linaclotide Brand 31 $34,668
Nurtec Odt Rimegepant Sulfate Brand 30 $34,498

The 10 drugs with the highest cost, of 143 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$21,701

Of which drugs: $1,889

Medicare patients

81

Average age 73

Services billed

1,043

48 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 36%
Arthritis 35%
Chronic kidney disease 30%
Ischemic heart disease 22%
Atrial fibrillation 15%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 22 22 $1,800

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $208
$208 60 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $109
$109 12 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $88
$88 — —
UBRELVY
  • AbbVie, Inc. $68
$68 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

457 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record